Fosun Pharmaceutical (02196) Holding Subsidiary's Integrated Nuclear Drug Project SRT-007 Starts Phase I Clinical Trials in China

Zhitongcaijing · 12/30/2025 11:33

Zhitong Finance App News, Fosun Pharmaceutical (02196) announced that recently, the company's holding subsidiary, Chengdu Xingrui Jingxuan Biotechnology Co., Ltd. initiated phase I clinical trials in China (excluding Hong Kong, Macao and Taiwan regions of China, same as below) for the diagnosis and treatment of PSMA-positive metastatic castration-resistant prostate cancer.